DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls
| Ticker |
TENX
|
| CIK | 0000034956 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 101 GLEN LENNOX DRIVE, SUITE 300, CHAPEL HILL, NC, 27517 |
| Website | tenaxthera.com |
| Phone | 919-855-2100 |
| CEO | Christopher T. Giordano |
| Employees | 9 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
DraftKings, Eli Lilly downgraded: Wall Street's top analyst callsDraftKings, Eli Lilly downgraded: Wall Street's top analyst calls Tenax Therapeutics: Q4 Earnings SnapshotThe Chapel Hill, North Carolina-based company said it had a loss of 38 cents per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.26 per share. Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateAchieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients to remain on drug CHAPEL HILL, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare ConferenceCHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the 2026 Leerink Partners Global Healthcare Conference, which is taking place from March 8-11, 2026, in Miami, FL. Details of presentation:Format: Fireside chatPa Tenax Therapeutics Shares Phase III Levosimendan Progress, H2 Data Timeline at Guggenheim ConferenceExecutives from Tenax Therapeutics (NASDAQ:TENX) outlined progress on the company’s Phase III development program for levosimendan in pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) during a fireside chat at Guggenheim’s Emerging Outlook Biotech Confe |